# A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

> **NCT05382325** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 70 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** MK-1484
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05382325
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-16
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382325, "A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05382325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*